Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn’s Disease
| Autor: | Fabiyola Selvaraj, Jane M. Andrews, William Connell, Michael A. Kamm, Emily K Wright, Timothy H. Florin, Lani Prideaux, Steven J. Brown, Graham L. Radford-Smith, Peter A. Bampton, Ian Kronborg, Amy L. Hamilton, Peter R. Gibson, Warwick Selby, Simon Jakobovits, Sally Bell, H.S. Debinski, Finlay A. Macrae, Danny Liew, Richard B. Gearry, Douglas Samuel, Peter De Cruz, Ian C. Lawrance, Fred Princen, Alexandra Gorelik |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Combination therapy Anti-Inflammatory Agents Severity of Illness Index Inflammatory bowel disease Gastroenterology Antibodies Feces Young Adult 03 medical and health sciences 0302 clinical medicine Crohn Disease Recurrence Internal medicine Secondary Prevention Adalimumab Humans Medicine Obesity Postoperative Period skin and connective tissue diseases Crohn's disease medicine.diagnostic_test Tumor Necrosis Factor-alpha business.industry General Medicine Middle Aged medicine.disease Ulcerative colitis Faecal calprotectin Infliximab Therapeutic drug monitoring 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Drug Monitoring business Leukocyte L1 Antigen Complex Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 12:653-661 |
| ISSN: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjy003 |
| Popis: | Anti-TNF prevents postoperative Crohn's disease recurrence in most patients but not all. This study aimed to define the relationship between adalimumab pharmacokinetics, maintenance of remission and recurrence.As part of a study of postoperative Crohn's disease management, some patients undergoing resection received prophylactic postoperative adalimumab. In these patients, serum and fecal adalimumab concentration and serum anti-adalimumab antibodies [AAAs] were measured at 6, 12 and 18 months postoperatively. Levels of Crohn's disease activity index [CDAI], C-reactive protein [CRP] and fecal calprotectin [FC] were assessed at 6 and 18 months postoperatively. Body mass index and smoking status were recorded. A colonoscopy was performed at 6 and/or 18 months.Fifty-two patients [32 on monotherapy and 20 on combination therapy with thiopurine] were studied. Adalimumab concentration did not differ significantly between patients in endoscopic remission vs recurrence [Rutgeerts ≥ i2] [9.98µg/mL vs 8.43 µg/mL, p = 0.387]. Patients on adalimumab monotherapy had a significantly lower adalimumab concentration [7.89 µg/mL] than patients on combination therapy [11.725 µg/mL] [p = 0.001], and were significantly more likely to have measurable AAA [31% vs 17%, p = 0.001]. Adalimumab concentrations were lower in patients with detectable AAA compared with those without [3.59 µg/mL vs 12.0 µg/mL, p0.001]. Adalimumab was not detected in fecal samples. Adalimumab serum concentrations were lower in obese patients compared with in non-obese patients [p = 0.046].Adalimumab concentration in patients treated with adalimumab to prevent symptomatic endoscopic recurrence postoperatively is, for most patients, well within the therapeutic window, and is not significantly lower in patients who develop recurrence compared with in those who remain in remission. Mechanisms of anti-TNF failure to prevent postoperative recurrence remain to be determined in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |